Siavash Piran1, Vincent Ngo2, Sheryl McDiarmid3, Grégoire Le Gal4, William Petrcich2, Marc Carrier5. 1. Medicine, University of Ottawa, Ottawa, ON, Canada. 2. Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, ON, Canada. 3. The Ottawa Hospital, Ottawa, ON, Canada. 4. Medicine, University of Ottawa, Ottawa, ON, Canada; Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, ON, Canada. 5. Medicine, University of Ottawa, Ottawa, ON, Canada; Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, ON, Canada. Electronic address: mcarrier@Ottawahospital.on.ca.
Abstract
INTRODUCTION: The true incidence of symptomatic implanted port related venous thromboembolism (VTE) in cancer patients is unclear and there is very limited data on its associated risk factors. MATERIALS AND METHODS: We performed a retrospective cohort study of consecutive cancer outpatients who received an ultrasound guided implanted port insertion for the administration of chemotherapy. The primary outcome measure was symptomatic VTE. Univariable and multivariable logistic regression analyses were used to identify risk factors for symptomatic VTE. RESULTS: A total of 400 cancer patients with a newly inserted implanted port for deliverance of chemotherapy were included in the study. Median age was 58years (range of 21 to 85years) and 120 (30%) were males. Patients were followed for a median of 12months and none received thrombophrophylaxis. Of the 400 patients included in the analysis, 34 patients (8.5%; 95% CI: 6.0 to 11.7%) had symptomatic VTE (16 DVTs, 16 PEs, and 2 with both). In the univariate analyses, metastatic disease, male gender and right sided implanted port insertion were significantly associated with the risk of VTE. In the multiple-variable analysis, male gender (OR 2.17, p=0.04) and presence of metastases (OR 8.22, p<0.01) were the two significant independent predictors of implanted port related VTE. CONCLUSION: Symptomatic VTE is a frequent complication in cancer patients with implanted port receiving chemotherapy. Gender and presence of metastatic disease are independent risk factors for symptomatic VTE. Future trials assessing the role of thromboprophylaxis among these higher risk patients are needed.
INTRODUCTION: The true incidence of symptomatic implanted port related venous thromboembolism (VTE) in cancerpatients is unclear and there is very limited data on its associated risk factors. MATERIALS AND METHODS: We performed a retrospective cohort study of consecutive cancer outpatients who received an ultrasound guided implanted port insertion for the administration of chemotherapy. The primary outcome measure was symptomatic VTE. Univariable and multivariable logistic regression analyses were used to identify risk factors for symptomatic VTE. RESULTS: A total of 400 cancerpatients with a newly inserted implanted port for deliverance of chemotherapy were included in the study. Median age was 58years (range of 21 to 85years) and 120 (30%) were males. Patients were followed for a median of 12months and none received thrombophrophylaxis. Of the 400 patients included in the analysis, 34 patients (8.5%; 95% CI: 6.0 to 11.7%) had symptomatic VTE (16 DVTs, 16 PEs, and 2 with both). In the univariate analyses, metastatic disease, male gender and right sided implanted port insertion were significantly associated with the risk of VTE. In the multiple-variable analysis, male gender (OR 2.17, p=0.04) and presence of metastases (OR 8.22, p<0.01) were the two significant independent predictors of implanted port related VTE. CONCLUSION: Symptomatic VTE is a frequent complication in cancerpatients with implanted port receiving chemotherapy. Gender and presence of metastatic disease are independent risk factors for symptomatic VTE. Future trials assessing the role of thromboprophylaxis among these higher risk patients are needed.
Authors: N LeVasseur; C Stober; K Daigle; A Robinson; S McDiarmid; S Mazzarello; B Hutton; A Joy; D Fergusson; J Hilton; M McInnes; M Clemons Journal: Curr Oncol Date: 2018-08-14 Impact factor: 3.677
Authors: Eric Voog; Loïc Campion; Pauline du Rusquec; Hugues Bourgeois; Julien Domont; Fabrice Denis; Eric Emmanuel; Olivier Dupuis; Gérard Ganem; Cedrik Lafont; Katell Le Du; Elena Pavluc; Yohan Pointreau; Sophie Roche; Laurence Juhel-Voog; Marie Zinger; Philippe Solal-Celigny Journal: Support Care Cancer Date: 2017-07-29 Impact factor: 3.603
Authors: Ye Liu; Li-Li Li; Lei Xu; Dong-Dong Feng; Yu Cao; Xiao-Yun Mao; Jin Zheng; Feng Jin; Bo Chen Journal: Biomed Res Int Date: 2020-02-13 Impact factor: 3.411